Tafamidis Accord (tafamidis)

Where it stands

Tafamidis Accord (tafamidis) is authorised in the EU. The marketing authorisation holder is Accord Healthcare S.L.U. The CHMP adopted a positive opinion on 2026-07-23, and the European Commission decision followed on 2026-09-18, about 57 days later. That is within the usual window for the Commission to turn a CHMP opinion into a legally binding decision.

The recorded indication is treatment of hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTRh-CM). The therapeutic areas are listed as Amyloidosis, Familial and Cardiomyopathies.

The records show the same substance already authorised in the EU as Vyndaqel. This product is therefore not the first tafamidis medicine on the EU market. The records give no launch dates, presentations or marketing status.

Regulatory pathway and designations

The only designation recorded is Generic. In general, a generic application relies on the data package of an already authorised reference medicine. The applicant mainly demonstrates pharmaceutical quality and bioequivalence, rather than repeating the full clinical programme. The records do not name the reference product, the legal basis or the type of procedure. They list Vyndaqel only as the same substance authorised elsewhere in the EU, so it should not be assumed to be the formal reference product.

Both milestones are marked official: the CHMP positive opinion and the EC approval. No orphan, PRIME, conditional approval or exceptional-circumstances status is recorded. The records say nothing on any orphan market exclusivity or orphan similarity assessment that might apply to this substance and indication.

The records also do not allow a comparison of this indication wording with that of Vyndaqel. Anyone assessing scope should check the approved product information of both medicines directly.

Safety and pharmacovigilance

The records contain no safety data, such as adverse reaction profiles, contraindications, risk management plan content or post-authorisation commitments. This analysis therefore makes no safety statements about the product.

As general procedure, EU generics are expected to align their product information with the reference medicine. They are subject to routine pharmacovigilance, including signal detection and periodic safety reporting under the EU framework. Whether any additional risk minimisation measures apply here is not stated in the records.

What to watch

The records do not cover commercial launch timing, national pricing and reimbursement, patent or data-exclusivity position, or any US or other regional filings. They are silent on all of these, so none can be assessed here.

Practical next steps for a professional reader are to review the published EPAR and SmPC for the authorised indication wording, to confirm the reference product and legal basis, and to track member-state launch notifications. It is also worth monitoring the authorised tafamidis medicines for any class-wide safety updates, since the records show Vyndaqel as the same substance in the EU.